# Oligomerix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oligomerix

- Industry: Pharmaceuticals
- Headquarters: White Plains, US
- Website: http://www.oligomerix.com
- Total disclosed funding: $5.2M
- Latest round: Series B (Apr 15, 2015)
- Investors on record: 1

## About

Founded in 2006 and based in New York, US, Oligomerix Inc. develops drugs targeting tau oligomers, a toxic form of the protein, for diseases like Alzheimer's, frontotemporal dementia, and amyotrophic lateral sclerosis (ALS). In March 2022, Oligomerix, Inc. raised USD 2.44 million in Series B funding. As of March 2022, the company is led by CEO James Moe.


Oligomerix's primary research and development is on a small-molecule inhibitor named OLX07010. This drug aims to disrupt the initial stages of tau protein aggregation, potentially preventing the progression of the disease through small-molecule drug discovery, immunotherapy approaches, and biomarker assay development for Alzheimer’s disease (AD) and other neurodegenerative disorders. The company uses full-length tau without mutations under conditions that naturally promote oligomer formation, avoiding artificial enhancers like heparin. This methodology closely mimics the natural disease process, enhancing the potential efficacy of its therapeutic candidates.
 
 The company will use the March 2022 funding to speed up its transition into Phase 1 human clinical development and further conduct research on its assets in the second-generation series.

## Funding rounds

- Series B, Apr 15, 2015, $0.4M — Wheatley Partners
- Series B, May 22, 2013, $2.8M — Wheatley Partners
- Series A, Apr 23, 2012, $2M — Wheatley Partners

## Investors

- Wheatley Partners (https://capitalatlas.ai/funds/wheatley-partners) — Series A, Series B